Keyword: Boehringer Ingelheim
Two months of treatment with the diabetes drug Jardiance reduced pulmonary congestion and biomarkers of heart failure in pig models.
AgomAb Therapeutics is coming out of stealth with €21 million to develop agonistic monoclonal antibodies that could potentially treat a range of diseases.
Appetite for biotech IPOs still appears high as Hookipa Pharma filed for a meaty public offering to boost its midstage cancer and infectious disease work.
The Canada-based units of Boehringer Ingelheim and IBM will work together to employ blockchain record-keeping technology in clinical trials.
BI will work with Vanderbilt to develop novel small molecules that they believe will relieve symptoms including memory loss.
Domain Therapeutics has another big pharma partner, signing a deal with Boehringer Ingelheim to develop new drugs for CNS disorders.
In a collaboration worth up to $300 million or more, Boehringer Ingelheim tapped Epizyme to help research two regulators of genes linked to cancer.
Boehringer Ingelheim Venture Fund co-led the financing to tee Amal up to take lead colorectal cancer vaccine ATP128 into the clinic next year.
Two dual EGFR/HER2 inhibitors from Boehringer Ingelheim and Puma showed in vitro activity against AML cancer cells.
Chris Corsico left the CMO spot at Boehringer Ingelheim to fill a new role at GlaxoSmithKline: senior vice president of development.